Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The systemic amyloidoses.

Joel N Buxbaum1

  • 1Department of Rheumatology, Division of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA. jbux@scripps.edu

Current Opinion in Rheumatology
|December 16, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis·2024
Same author

The Role of CSF Transthyretin in Human Alzheimer's Disease: Offense, Defense, or not so Innocent Bystander.

Journal of integrative neuroscience·2024
Same author

Age Dependency of Cardiovascular Outcomes With the Amyloidogenic pV142I Transthyretin Variant Among Black Individuals in the US.

JAMA cardiology·2023
Same author

Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis·2022
Same author

Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis.

Hemato·2022
Same author

Evidence From Human Placenta, Endoplasmic Reticulum-Stressed Trophoblasts, and Transgenic Mice Links Transthyretin Proteinopathy to Preeclampsia.

Hypertension (Dallas, Tex. : 1979)·2022

Amyloidosis research reveals protein misfolding drives disease, with new therapies targeting precursor stabilization, cell elimination, and fibril disruption. Future treatments will clarify the value of these innovative approaches for managing amyloid disorders.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Genetics

Background:

  • Amyloidosis management traditionally involved rheumatologists due to links with chronic inflammatory diseases.
  • Current interest spans nephrology, hematology-oncology, neurology, and transplant surgery.
  • Advances in physical biochemistry, cell biology, and genetics are transforming amyloidosis diagnosis and treatment.

Purpose of the Study:

  • To review current understanding of amyloidosis pathogenesis, focusing on protein misfolding.
  • To explore emerging diagnostic and therapeutic strategies for amyloid disorders.
  • To discuss the implications of new research on protein conformation and disease.

Main Methods:

  • Analysis of protein misfolding pathways leading to amyloid aggregation.

Related Experiment Videos

  • Review of specific amyloidogenic precursors including transthyretin, immunoglobulin light chains, beta2 microglobulin, and apolipoprotein A1.
  • Synthesis of current therapeutic approaches and their underlying mechanisms.

    • Main Results:

    • All amyloidogenic precursors involve protein misfolding, leading to rapid aggregation.
    • Mechanisms include abnormal proteolysis, mutations affecting protein stability, and undefined pathways.
    • Therapies target precursor stabilization, cell elimination, fibril disruption, and inflammatory processes.

    Conclusions:

    • Understanding protein misfolding is crucial for amyloidosis pathogenesis.
    • Multiple therapeutic strategies are under investigation, showing promise for future clinical application.
    • Continued research into protein behavior and cellular processes will refine amyloidosis management.